PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Adolescent, Institutionalized”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23Linked to original sources
PubMed1981

Prevalence and treatment of intestinal helminthic infections among children in orphanages in Jakarta, Indonesia.

A survey was carried out in three orphanages in Jakarta for intestinal helminthic infections. Stool samples and anal swabs of 158 children were examined. The prevalences of intestinal helminthic infections in the Putra Utama, Muslimin and Van der Steur orphanages were respectively as follows: a lumbricoides 70.0%, 76.6% and 50.8%, T. trichiura 78.0% 93.6% and 70.5%, hookworm 20.0%, 12.7% and 3.2% and E. vermicularis 34.0% 29.8%, 59.0%. Treatment with Trivexan (100 mg of pyrantel pamoate and 150 mg of mebendazole), one tablet as a single daily dose for 3 consecutive days resulted in cure rates for A. lumbricoides 96.0%, 100% for T. trichiura 78.0%, 80.9% and 86.9% for hookworm 98.0%, 100% and 100% and for E. vermicularis 82.3% 92.9% and 97.2%. No side effects were observed, except in one child who complained of nausea.

Adolescent↗
PubMed1997

[Immunogenicity of the Heberbiovac-HB vaccine in the physically and mentally handicapped].

The recombinant DNA Heberbiovac-HB vaccine against hepatitis B was applied to 2 groups of children at 2 homes for the physically and mental disabled at doses of 10 and 5 micrograms with the scheme 0, 1 and 6 months to study its immunogenicity, which was evaluated at 2, 7 and 12 months after the first dose was administered. On the 60th day it was obtained 80.9% of seroprotection in children who received 10 micrograms, whereas in the group that was vaccinated with 5 micrograms 65.0% of seroprotection was attained and there were no significant differences between the groups. 100% of seroprotection (> or = 10 UI/L) was obtained in the 2 vaccinated groups when the immune response was measured 1 month after the third dose was applied. A year later, seroprotection was 100% for the 2 groups of children. The geometrical mean of the antibody titres (TMG) reached levels above 10 UI/L, which is the minimum protector, in the 2 study groups 30 days after the second dose. A month after the third dose, the TMG attained values of 527.7 UI/L in the group of 10 micrograms and of 324.7 UI/L in that of 5 micrograms. No remarkable differences were found between the groups (p < 0.05). Finally, 365 days later, the TMG descended to 139.7 UI/L and 57.3 UI/L in the same groups, respectively. It was demonstrated the high immunogenic power of this vaccine, which makes it recommendable for protecting the physical and mentally disabled children from hepatitis B virus.

Adolescent↗
PubMed1999

Methods of adolescent suicide prevention.

This article reviews a series of studies developed to address the public health problem of adolescent suicide. The clinical predictors of adolescent suicide are presented, and several related prevention strategies are offered and critiqued. The method of suicide prevention found to be most effective is a systematic, direct-screening procedure that has a high potential for institutionalization.

Adolescent↗